argenx (NASDAQ:ARGX) Receives “Buy” Rating from HC Wainwright

argenx (NASDAQ:ARGX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $451.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 23.16% from the stock’s previous close.

Several other analysts have also recently issued reports on ARGX. William Blair cut shares of argenx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Evercore ISI lowered their target price on shares of argenx from $594.00 to $436.00 and set an “outperform” rating on the stock in a research note on Thursday, December 21st. Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Tuesday, March 26th. Truist Financial increased their price target on shares of argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $530.74.

argenx Stock Performance

Shares of ARGX stock opened at $366.20 on Thursday. The firm has a market cap of $21.72 billion, a price-to-earnings ratio of -71.25 and a beta of 0.65. argenx has a 52 week low of $327.73 and a 52 week high of $550.76. The firm’s 50-day simple moving average is $388.98 and its two-hundred day simple moving average is $422.26.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the firm posted ($0.70) EPS. Analysts forecast that argenx will post -2.11 earnings per share for the current year.

Hedge Funds Weigh In On argenx

Several large investors have recently added to or reduced their stakes in ARGX. KB Financial Partners LLC lifted its holdings in argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in argenx during the fourth quarter valued at approximately $27,000. Parkside Financial Bank & Trust purchased a new position in argenx during the third quarter valued at approximately $28,000. GAMMA Investing LLC lifted its holdings in argenx by 420.0% during the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after purchasing an additional 63 shares in the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in argenx during the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.